Lacosamide Xiromed (Lacosamide)

Lacosamide is an anticonvulsant used as adjunctive therapy for seizure disorders.

• Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic regimens.
• Primary generalized tonic‑clonic seizures: provides additional seizure control in refractory cases.
• Epilepsy (overall): contributes to overall seizure management as part of combination therapy.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing hyperexcitability. It also modulates the collapsin response mediator protein‑2 (CRMP2), influencing neuronal signaling pathways that contribute to seizure activity.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: feeling of stomach upset or urge to vomit.
• Headache: mild to moderate pain in the head region.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention.
• Cardiac conduction abnormalities: changes in heart rhythm that may need monitoring.
• Suicidal ideation: thoughts of self‑harm that should be reported promptly.
• Severe hypersensitivity: rash, swelling, or breathing difficulty indicating an allergic response.

Before initiating therapy, consider the following precautions.

• Renal impairment: dose may need adjustment based on kidney function.
• Hepatic impairment: monitor liver enzymes and adjust dosing if necessary.
• Cardiac conduction disorders: obtain baseline ECG and monitor for arrhythmias.
• Pregnancy: use only if potential benefit outweighs potential risk to the fetus.
• Drug interactions: review all concomitant medications for possible interactions.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Lacosamide can interact with several medicines; assess the clinical relevance before co‑administration.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine): may markedly reduce lacosamide plasma levels.
• Other sodium‑channel blockers (e.g., phenytoin): increased risk of central nervous system depression.
• QT‑prolonging agents: may exacerbate cardiac conduction effects.

Moderate Interactions (Monitor Closely)

• Additional antiepileptics (e.g., valproate): may require dose adjustments based on therapeutic response.
• Alcohol: can enhance dizziness and somnolence, necessitating caution.